Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

g and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase((R))), a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic). Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with currently-available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance. Viradin((TM)), invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. TOSAP((TM)) is a technology invented and developed by NexBio and is used to formulate DAS181 for inhalation, as well as to make nano/microparticles from virtually any type of molecule. TOSAP((TM)) is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

* FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015   InspireMD, Inc. (NYSE ... protection systems, announced today that it will release its full ... 31, 2014 on Thursday, March 12 th after market ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:3/6/2015)... , March 6, 2015 BioSpecifics Technologies ... developing first in class collagenase-based products marketed as XIAFLEX ... U.S. and XIAPEX ®  in the EU, announced today ... audio webcast at 8:30 a.m. ET on Friday, March ... year 2014 financial results and provide a corporate update. ...
(Date:3/6/2015)... March 6, 2015 ... 2011 von der Assistance Publique - Hôpitaux ... Sie ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie ... rekrutiert wurden. Verglichen werden Patienten mit fortgeschrittenem ... Harz-Mikrosphären oder Sorafenib behandelt wurden. Die Ergebnisse ...
(Date:3/5/2015)... 05, 2015 Plant disease specialists from ... at the Annual Meeting of The American Phytopathological Society. ... released online now at APSnet.org/meet . , The ... meeting, to be held August 1-5, 2015 in Pasadena, ... Field Trips, Workshops, and committee meetings, all carefully balanced ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... ... Vein and Skin Care Center. Tokyo Vein Clinic visited , for a close up look at ... back to patients in Japan. , ... June 16, 2010 -- The Japanese have a long history of being on the cutting edge. ...
... ... found dead four days after receiving the Gardasil vaccine has filed an amicus ... asked to bar lawsuits against manufacturers of defectively designed vaccines. The mother ... a lessened incentive to produce a safe vaccine and public trust in the ...
... ... ... The American Medical Writers Association named medical writer, Rita Buckley, Writer/Owner of medical ... Medical Communication. She received the awards for The Lehman Series Expert Panel on Weight ...
Cached Biology Technology:OnychoLase Laser Nail Centers Making a Global Impact, By Bringing Western Medicine To The East 2Supreme Court Amicus Brief Filed Opposing Lawsuit Protection for Manufacturers of Defectively Designed Vaccines 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 3
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... 2012 In 2012 Wiley-Blackwell, the Scientific, Technical, Medical, ... Inc., will begin publishing 44 titles new to its ... published in collaboration with societies or other organizations. ... the course of 2012 include Advanced Healthcare Materials ...
... the aid of light: this is made possible ... of neurobiological processes with unprecedented spatial and temporal ... light-activated protein channelrhodopsin. Biophysicists from Bochum and Berlin ... through an interdisciplinary approach. The researchers report on ...
... drug may be useful in fighting malaria, researchers report in ... protozoa, the drug readily crosses into the red blood cells ... works at very low concentrations with no observed toxicity to ... of the National Academy of Sciences . The researchers ...
Cached Biology News:Wiley-Blackwell adds 44 titles to journal publishing program in 2012 2Optogenetic tool elucidated 2Modified bone drug kills malaria parasite in mice 2
... dihydrochloride) is a fluorescent counterstain ... in color. The bright blue ... red fluorochromes such as rhodamine, ... DAPI can be used for ...
... sets of glass plates, bar clamp, and ... features of these units are:, safety interlock ... reservoirs , upper and lower reservoirs have ... safe disposal of buffer solutions , leveling ...
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: